베바시주맙과 함께 올라파립의 이점을 가져오는 HRD 상태(STROBE 시험) (STROBE)
진행성 FIGO 3기-4기 고등급 장액성 또는 자궁내막양 난소, 나팔관 또는 복막 환자에서 올라파립과 베바시주맙 병용의 이점으로 이어지는 HRD 상태를 더 잘 특성화하기 위한 비무작위, 공개, 전향적 2상 시험 표준 1차 치료 후 암
Background:
The study aims to address the challenge of accurately identifying patients with ovarian cancer who would benefit from poly-ADP ribose inhibitors (PARPi) as first-line maintenance therapy. While BRCA1/2-mutated epithelial ovarian cancer (EOC) patients have shown significant benefits from PARPi treatment, the efficacy in homologous recombination deficient (HRD) patients remains inconclusive. Current assays used to estimate HR status do not effectively differentiate between patients who benefit most from PARPi and those who do not, making it inefficient to treat all patients. There is a need for a more accurate HR status testing method to optimize PARPi benefit. This study aims to assess the performance of the VHIO-CARD-300 test in determining HR status compared to SOPHiA DDM™ Dx HRD Solution.
Summary:
The study is a prospective, non-randomized trial designed to evaluate the concordance of the VHIO-CARD-300 test in establishing HR status compared to SOPHiA DDM™ Dx HRD Solution. Additionally, it aims to assess the association between HRD status determined by the VHIO-CARD-300 test and treatment efficacy. Patients with advanced FIGO stage III-IV high grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer will be invited to participate. Those eligible will undergo testing with both VHIO-CARD-300 and SOPHiA DDM™ Dx HRD Solution. Patients classified as HRD positive will receive olaparib in combination with bevacizumab, while others will receive bevacizumab alone. Treatment will be administered according to approved doses, with follow-up evaluations conducted until RECIST progression.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
This non-randomized, open-label phase II trial seeks to enhance our understanding of HRD status in patients with advanced ovarian, fallopian tube, or peritoneal cancer. Following standard first-line treatment, participants will be assessed for HRD status using the VHIO-CARD-300 test and SOPHiA DDM™ Dx HRD Solution. Those identified as HRD-positive will receive olaparib in combination with bevacizumab, while others will receive bevacizumab alone as per standard care. The study aims to determine the concordance between the two HRD tests, evaluate the efficacy of the olaparib-bevacizumab combination, and assess safety and tolerability. Efficacy outcomes will be evaluated using RECIST criteria, with a minimum follow-up of 30 months post-enrollment. Secondary objectives include examining treatment accuracy, association with efficacy outcomes, and analyzing discrepant cases. Overall, this trial aims to provide valuable insights into personalized treatment approaches for patients with advanced ovarian cancer.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Ana Oaknin
- 전화번호: 2658 +34 934893000
- 이메일: aoaknin@vhio.net
연구 장소
-
-
-
Barcelona, 스페인
- 모병
- Vall d'Hebron Institute of Oncology
-
연락하다:
- Ana Oaknin
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Patient with newly diagnosed high- grade serous or endometrioid Ovarian cancer, primary peritoneal cancer and/or fallopian-tube cancer. I-3-3 At an advanced stage: FIGO stage IIIB, IIIC, or IV of the 1988 FIGO classification (see appendix 1).
-
Patient who has completed prior to enrollment first line platinum-taxane chemotherapy:
- Platinum-taxane based regimen must have consisted of
- minimum of 6 treatment cycles and a maximum of 8. However, if platinum-based therapy must be discontinued early as a result of non-hematological toxicityspecificallyrelated to the platinum regimen, (i.e. neurotoxicity, hypersensitivity etc.), patient must have received a minimum of 4 cycles of the platinum regimen.
- Patient must have received prior to enrollment a minimum of 3 cycles of bevacizumab in combination with the 3 last cycles of platinum-based chemotherapy. Only in case of interval debulking surgery, it is allowed to realize only 2 cycles of bevacizumab in combination with the last 3 cycles of platinum-based chemotherapy.
-
Patient must be prior to enrollment without evidence of disease (NED) or in complete response (CR) or partial response (PR) from the first line treatment. There should be no clinical evidence of disease progression (physical exam, imagery, CA 125) throughout he first line treatment and prior to study enrollment.
-
Patient must be randomized at least 4 weeks and no more than 8 weeks after her last dose of chemotherapy (last dose is the day of the last infusion) and all major toxicities from theprevious chemotherapy must have resolved to CTCAE grade 1 or better (except alopecia and peripheral neuropathy).
-
Patient must have normal organ and bone marrow function:
-
Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (see appendix 3)
-
Formalin fixed, paraffin embedded (FFPE) tumor sample from the primary cancer must be available for central BRCA testing and test result must be available for stratification.
Exclusion Criteria:
-
Non-epithelial origin of the ovary, the fallopian tube or the peritoneum (i.e. germ cell tumors).
-
Ovarian tumors of low malignant potential (e.g. borderline tumors) or mucinous carcinoma.
-
Other malignancy within the last 5 years except:
-
Patient with myelodysplastic syndrome/acute myeloid leukemia history.
-
Major surgery within 4 weeks of starting study treatment and patient must have recovered from any effects of any major surgery.
-
Any previous treatment with PARP inhibitor, including olaparib.
-
Concomitant use of known potent CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin and nelfinavir.
-
Prior history of hypertensive crisis (CTC-AE grade 4) or hypertensive encephalopathy.
-
Clinically significant (e.g. active) cardiovascular disease, including:
- Myocardial infarction or unstable angina within ≤ 6 months of enrollment,
- New York Heart Association (NYHA) ≥ grade 2 congestive heart failure (CHF) (see appendix 5).
- Poorly controlled cardiac arrhythmia despite medication (patient with rate controlled atrial fibrillation are eligible), or any clinically significant abnormal finding on resting ECG,
- Peripheral vascular disease grade ≥ 3 (e.g. symptomatic and interfering with activities of daily living [ADL] requiring repair or revision)
-
Previous Cerebro-Vascular Accident (CVA), Transient Ischemic Attack (TIA) or Sub-Arachnoids Hemorrhage (SAH) within 6 months prior to enrollment.
-
History or evidence of hemorrhagic disorders within 6 months prior to enrollment.
-
History or clinical suspicion of brain metastases or spinal cord compression.
-
Significant traumatic injury during 4 weeks prior to enrollment.
-
Non-healing wound, active ulcer or bone fracture.
-
History of VEGF therapy related abdominal fistula or gastrointestinal perforation or active gastrointestinal bleeding within 6 months prior to the first study treatment.
-
Current, clinically relevant bowel obstruction, including sub-occlusive disease, related to underlying disease.
-
Patient with evidence of abdominal free air not explained by paracentesis or recent surgical procedure.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: HRD positive arm
Patient with harboring HRD tumor, that will receive olaparib in combination with bevacizumab |
Bevacizumab dosing is at 15 mg/kg every 3 weeks as an intravenous infusion. Olaparib dosing is oral at 300 mg twice daily |
|
다른: HRD negative arm
Control group receiving bevacizumab alone as standard of care.Patient with non harboring HRD tumor, that will receive bevacizumab |
Bevacizumab dosing is at 15 mg/kg every 3 weeks as an intravenous infusion. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Concordance in HRD status identification between VHIO-CARD-300 test and SOPHiA DDM™ Dx HRD Solution
기간: Through study completion, an average of 1.5 years
|
The primary outcome measure description would outline the method used to evaluate the agreement in HRD status identification between the VHIO-CARD-300 test and SOPHiA DDM™ Dx HRD Solution. This would include details on how HRD status is determined and compared between the two tests, along with any statistical analyses employed to measure the level of agreement. |
Through study completion, an average of 1.5 years
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Performance Assessment of VHIO-CARD-300 Test for HR Status Identification
기간: Through study completion, an average of 1.5 years
|
This secondary outcome measure focuses on evaluating the performance of the VHIO-CARD-300 test as a diagnostic tool for identifying HR status. The assessment will include determining the sensitivity, specificity, and predictive positive and negative values of the VHIO-CARD-300 test, with the SOPHiA DDM™ Dx HRD Solution serving as the reference standard. |
Through study completion, an average of 1.5 years
|
|
Association Between VHIO-CARD-300 Test Groups and Efficacy Outcomes(i.e., HRD positive and HRD negative) and efficacy outcomes.
기간: Through study completion, an average of 1.5 years
|
To assess the relationship between the HRD positive and HRD negative groups identified by the VHIO-CARD-300 test and treatment efficacy outcomes. |
Through study completion, an average of 1.5 years
|
|
Analysis of Progression-Free Survival (PFS) and Overall Survival (OS) in Discrepant HRD Cases
기간: Through study completion, an average of 1.5 years
|
This outcome measure aims to assess the efficacy outcomes in cases where there is a discrepancy between the results obtained from the VHIO-CARD-300 test and the SOPHiA DDM™ Dx HRD Solution. Specifically, it focuses on cases where a patient is classified as HRD positive by one test but HRD negative by the other, and vice versa. The primary efficacy endpoints, progression-free survival (PFS) and overall survival (OS), will be analyzed in these discrepant cases to evaluate the impact of the discordant results on clinical outcomes |
Through study completion, an average of 1.5 years
|
|
Safety and Tolerability of Olaparib Plus Bevacizumab
기간: Through study completion, an average of 1.5 years
|
Assessment of adverse events (AEs) graded by the National Cancer Institute (NCI) CTCAE v5.0, serious adverse events (SAEs), abnormal vital signs, abnormal ECG results, and evaluation of laboratory parameters |
Through study completion, an average of 1.5 years
|
|
To evaluate the failure rate for the VHIOCARD-300 test and SOPHiA DD Dx HRD Solution.
기간: Through study completion, an average of 1.5 years
|
Percentage of inconclusive results will be estimated for each test |
Through study completion, an average of 1.5 years
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Ana Oaknin, Vall d'Hebron Institute of Oncology
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- ESR-20-21103
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .